Related Experiment Videos
Fibrinopeptide A, platelet factor 4, and beta-thromboglobulin levels in coronary heart disease
Insights
Platelet activation markers like platelet factor 4 and beta-thromboglobulin are elevated in patients with prior myocardial infarction, suggesting platelet release is linked to infarcted heart tissue, not just coronary artery disease.
Area of Science:
- Cardiovascular Medicine
- Hematology
- Biochemistry
Background:
- Ischemic heart disease involves complex platelet activation and fibrin formation.
- Understanding the triggers for platelet release is crucial for managing cardiovascular events.
Purpose of the Study:
- To investigate in vivo platelet alpha-granule release and fibrin formation in patients with ischemic heart disease.
- To determine the relationship between platelet activation markers and the extent of coronary artery disease and left ventricular dysfunction.
Main Methods:
- Radioimmunoassay was used to measure platelet factor 4, beta-thromboglobulin, and fibrinopeptide A levels in 82 patients.
- Coronary arteriography assessed coronary artery disease, and contrast left ventriculography evaluated left ventricular dysfunction.
Main Results:
- Elevated platelet factor 4 and beta-thromboglobulin levels were observed in patients with prior myocardial infarction, but not in those without infarction.
- Platelet activation markers did not correlate with the extent of coronary artery disease.
- Beta-thromboglobulin levels correlated with left ventricular dysfunction and inversely with ejection fraction in patients with prior infarction.
- Elevated fibrinopeptide A levels were noted in a small group with left ventricular aneurysm.
Conclusions:
- Platelet release in ischemic heart disease appears to be primarily driven by reactions with previously infarcted myocardium.
- These findings suggest that platelet activation is more closely associated with myocardial damage than with atherosclerotic coronary arteries.
Abstract:
In vivo platelet alpha-granule release and fibrin I formation were measured in 82 patients with ischemic heart disease by radioimmunoassay of platelet factor 4, beta-thromboglobulin, and fibrinopeptide A. The presence and extent of coronary artery disease were determined by coronary arteriography, and the extent of left ventricular regional dysfunction was assessed by contrast left ventriculography. In patients with abnormal coronary arteriograms without previous myocardial infarction, mean levels of platelet factor 4, beta-thromboglobulin, and fibrinopeptide A were not elevated. In patients in whom myocardial infarction had occurred more than 6 mo previously, platelet factor 4 (8.3 ng/ml; p less than 0.01) and beta-thromboglobulin (33.2 ng/ml; p less than 0.001) levels were significantly elevated, but fibrinopeptide A levels were normal. Levels of platelet factor 4 and beta-thromboglobulin were unrelated to the extent of coronary artery disease. In the patients with prior infarction, beta-thromboglobulin correlated directly with extent of left ventricular regional dysfunction (r = 0.53; p less than 0.01) and inversely with ejection fraction (r = -056; p less than 0.05). In a small group of patients with left ventricular aneurysm, mean fibrinopeptide A levels were also elevated. We interpret these findings as indicating that platelet release in patients with ischemic heart disease results from platelet reaction with previously infarcted myocardium rather than with the atherosclerotic coronary arteries.